 |
Cyclacel Pharmaceuticals Announces Closing of Underwritten Offering
May 21, 2013
|
13.4 KB |
|
| |
BERKELEY HEIGHTS, N.J., May 21, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that it has closed its previously announced underwritten offering of 6,833,334 shares of its common stock at a price to the public of $3.00 per share (which includes 166,667 shares of common...
|
|
Cyclacel Pharmaceuticals Announces $20 Million Underwritten Offering
May 16, 2013
|
14.2 KB |
|
| |
BERKELEY HEIGHTS, N.J., May 16, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced the pricing of the underwritten offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. Cyclacel has granted the underwriters a 30-day option to purchas...
|
|
Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 15, 2013
|
13.6 KB |
|
| |
BERKELEY HEIGHTS, N.J., May 15, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that it is offering to sell, subject to market and other conditions, shares of its common stock in an underwritten offering. Cyclacel also expects to grant the underwriters a 30-day option t...
|
|
Cyclacel Reports First Quarter 2013 Financial Results
May 13, 2013
|
26.1 KB |
|
| |
BERKELEY HEIGHTS, N.J., May 13, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and b...
|
|
Cyclacel Pharmaceuticals to Announce Release of First Quarter 2013 Financial Results
May 10, 2013
|
12.2 KB |
|
| |
BERKELEY HEIGHTS, N.J., May 10, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders will announce first quarter 2013 financial ...
|
|
Cyclacel Reports Updated Phase 2 Survival Data of Sapacitabine for MDS
Apr 30, 2013
|
18.4 KB |
|
| |
BERKELEY HEIGHTS, N.J., April 30, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), announced updated median overall survival data from an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, the Company's lead product candidate, in older patients with intermedia...
|
|
Cyclacel Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference
Apr 23, 2013
|
12.3 KB |
|
| |
BERKELEY HEIGHTS, N.J., April 23, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced that the Company will present at the Needham and Company 12th Annual Healthcare Conference, being held at the Westin Grand Central Hotel in New York City. Spiro Rombotis, President and ...
|
|
Combination Potential of Cyclacel's Sapacitabine and Seliciclib Reported at AACR
Apr 9, 2013
|
18.7 KB |
|
| |
BERKELEY HEIGHTS, N.J., April 9, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced updated data from an open label, single arm, Phase 1 escalation trial of the Company's two product candidates, sapacitabine, a nucleoside analogue, and seliciclib, a cyclin-dependent kin...
|
|
AACR Press Conference Highlights Combination Potential of Two Cyclacel Drugs
Apr 8, 2013
|
13.9 KB |
|
| |
WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced that the American Association of Cancer Research (AACR) highlighted data at a press conference in Washington, D.C. from a clinical trial evaluating a novel combination regimen of two of the Company'...
|
|
Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene and Dismissal of All Claims in Their Patent Litigation
Apr 4, 2013
|
196.5 KB |
|
| |
BERKELEY HEIGHTS, N.J., April 4, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced that it has entered into a definitive agreement with Celgene Corporation ("Celgene") to sell to Celgene four Cyclacel‐owned patents related to the use of romidepsin injection. In connect...
|
|
Cyclacel Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting
Apr 3, 2013
|
14.4 KB |
|
| |
BERKELEY HEIGHTS, N.J., April 3, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that two abstracts highlighting...
|
|
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
Mar 27, 2013
|
31.8 KB |
|
| |
BERKELEY HEIGHTS, N.J., March 27, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today its financial results and business highlights for the fourth quarter and full year 2012. The Company's net loss applicable to common stockholders for the fourth quarter of 2012 was $4.9...
|
|
Cyclacel to Announce Year-End and Fourth Quarter 2012 Financial Results
Mar 22, 2013
|
12.4 KB |
|
| |
BERKELEY HEIGHTS, N.J., March 22, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce full year and fourth quart...
|
|
Cyclacel Announces Grants of New U.S. & European Patents Covering Sapacitabine Used in Combination With HDAC Inhibitors
Feb 12, 2013
|
16.2 KB |
|
| |
BERKELEY HEIGHTS, N.J., Feb. 12, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced the issuance of U.S. Pate...
|
|
Cyclacel Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference
Feb 4, 2013
|
13.3 KB |
|
| |
BERKELEY HEIGHTS, N.J., Feb. 4, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today announced that the Company will present at the 15th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, New York. Spiro Rombotis, President and Chief Executi...
|
|
Cyclacel Reviews 2012 Achievements and Announces Key Business Objectives for 2013
Jan 7, 2013
|
21.4 KB |
|
| |
- SEAMLESS DSMB recommended that the study should continue as planned - - Company to Present at the Biotech Showcase™ 2013 Conference on Monday January 7, 2013 at 3:15 pm PT -
BERKELEY HEIGHTS, N.J., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today reviewed 2012 a...
|
|
Cyclacel Enters Into a $20 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC
Dec 17, 2012
|
16.3 KB |
|
| |
BERKELEY HEIGHTS, N.J., Dec. 17, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it has entered into ...
|
| |
2012 ASH 682-11 Pilot and CYC682-12 lead-in Poster
Dec 10, 2012
|
413.9 KB |
|
|
Cyclacel Presents Updated Survival Data From the Pilot Study and Lead-In Phase of Seamless Phase 3 Study at the 2012 ASH Annual Meeting
Dec 10, 2012
|
18.9 KB |
|
| |
BERKELEY HEIGHTS, N.J., Dec. 10, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced updated survival data from the ...
|
|
Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Hematology Annual Meeting
Dec 4, 2012
|
13.4 KB |
|
| |
BERKELEY HEIGHTS, N.J., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders announced today that updated Phase 3 clinic...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter